. . . . . . . . . "Similarly, De Cos Milas et al. [6] described their clinical experience with paliperidone in adolescents. They presented 3 males and 2 females, age between 15 and 17 years. Diagnoses were autism, borderline personality dis- order, schizotypal personality disorder, personality disorder not otherwise specified, and schizophrenia. Prescribed dose was 3–9 mg/day, and actual mean time of treatment duration is 5.8 months. In 4 cases, paliperidone was initiated as a change from other antipsychotic. There were no adverse effects that required discontinuation and in all cases symptoms improved." . . . . . . "Adolescents (15-17)" . . "2021-08-24T16:13:49.733446"^^ . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB" . "IODet0dDO0nLdPxHcGX6FYYKvPWxDYGKVaA4kSMeek8UzsRO94kbb6dRvK3E1Ict6pV/n/ZIBFO81DlEqVmABcyA8T36OHTKa2B1XDCHOYgp4OV1zu3+n48IN7JToUlKeIOuYzN+0EyyGsyArByHBFg6VhZjTAy9CzctEAGa/ZE=" . . "2021-08-24T16:13:49.733446"^^ . . .